Berman Capital Advisors’s Aimmune Therapeutics AIMT Stock Holding History

Berman Capital Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-150	Closed	-$5K	–	1912
2020 Q3	$5K	Buy	+150	New	+$3.19K	﹤0.01%	1073

Berman Capital Advisors's AIMT Position: Q4 2020 in Review

Berman Capital Advisors sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 150 shares — an estimated $5K sold.

Berman Capital Advisors first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $5K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Berman Capital Advisors reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Berman Capital Advisors sold 150 Aimmune Therapeutics shares in Q4 2020, an estimated $5K.
Berman Capital Advisors first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
Berman Capital Advisors's Aimmune Therapeutics position peaked at $5K in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Berman Capital Advisors's 13F filing for Q4 2020, filed 11 Feb 2021.